Top Reasons to Use Natural Male Enhancer Pills
Premature ejaculation can be treated with Rhino Spark Male Enhancement is natural male enhancement pills
Premature ejaculation, the most common form of sexual dysfunction today, is undoubtedly the most prevalent. This problem is becoming more common as more men come out to speak out about it. Although big drug companies are working hard to find a prescription for premature ejaculation treatment, FDA approval is still decades away.
Male enhancers made from natural ingredients can be used to treat premature ejaculation. They contain powerful sexual nutrients, which allow men to have more sexual intercourse for longer periods. You don't have to worry about whether you will be able to last longer in the bedroom. Natural male enhancers provide you with all the tools you need to have a successful sexual experience.
Male Enhancer Pills will Increase Your Pleasure and Release
Are you looking for more pleasure and intense sexual encounters? This is one of the main reasons that more couples swear by natural male enhancement products or pills in the bedroom. Imagine if one pill could transform your sex experience so that it's almost like the first time you had it again? Natural male enhancers are used by some men to have better sex with their girls.
A natural male enhancer will help to stamp out erectile dysfunction
Did you know that you are not the only one who has erectile dysfunction? According to recent estimates, more than 30,000,000 adult males in the US suffer from erectile dysfunction. This is a significant number and it's not an inferior one.
Many people don't have insurance or can't afford prescription medications. Male pills are natural male supplements that work like drugs. They also cost less to purchase and take longer to deliver results. They are also very safe because they don't have side effects.
Low Testosterone Levels can be charged by natural male enhancements.
One of the most searched terms for male sexual terms is testosterone boosters. Because many men suffer from low testosterone levels, this is why it's so popular. Fear of humiliation makes it difficult for many to admit that they have ED. Many people are unable to afford or don't want to have expensive and invasive medical tests, or take the pills or shots.
Men should be concerned about side effects. Natural male enhancement pills are a viable and more affordable option. These pills use natural herbs and extracts to increase testosterone levels in men. They have amazing results. These natural enhancer pills contain natural ingredients that have been used for centuries by natives to increase their male libido. The use of roots such as the tongat Ali has been proven to increase sexual stamina for centuries.
Male Pills are more affordable and easier to obtain
Natural male enhancement pills and products are extremely affordable. This is especially true when compared with the traditional alternative, which can be expensive prescription drugs that need to be prescribed by a doctor and require tests, visits and trips to the pharmacist. Natural male enhancers can be found online, from your home, and at a fraction of the cost of prescription drugs.
They can be ordered discreetly online and delivered to your home right at your doorstep. You don't need prescriptions or doctor visits. Today, natural options such as male pills can empower your sex life. You have to act if you want to enjoy better sex.
Brad Heyson is an author who creates content for a variety of topics. He is passionate about writing and developing content. He is a post-graduate in management with an affinity for the English language and is a content writer who cares about providing quality content to his readers.
Actimed Therapeutics, the clinical stage company focused on bringing innovation to the treatment of muscle wasting disorders, with a focus on cachexia, today announces the appointment of Frank Misselwitz MD, PhD, as Chief Medical Officer.
Dr Misselwitz joins the Company in his new role from Bayer AG where until recently he was Corporate Vice President and Therapeutic Area Head in clinical development. With a background in academia and industry, he has over 30 years of extensive pharmaceutical industry experience. Dr Misselwitz is currently a non-executive director and member of the Board of Actimed.
Dr Misselwitz was a member of the Scientific Advisory Board (SAB) of the German Centre for Cardiovascular Research for 8 years and is currently a member of the SAB for the Centre for Thrombosis and Haemostasis University of Mainz, Germany.
Robin Bhattacherjee, Actimed CEO, commented: "We are tremendously excited to appoint Frank as our Chief Medical Officer as we seek to further advance the development of our lead candidate ACM-001 (S-pindolol) for cancer cachexia. Frank brings a wealth of international expertise in clinical development and an outstanding track record for delivering successful large-scale clinical trials on time. He is a highly respected and influential leader who shares our motivation to bring new medicines to the many patients suffering from cachexia."
During his career, Frank supported the development of Humira at Knoll AG and Abbott. While at Bayer, he led the successful development of multiple cardiovascular drugs including rivaroxaban, the leading oral direct FXa inhibitor. The rivaroxaban development programme included the landmark COMPASS trial, one of the largest and most complex development programs conducted, encompassing more than 275,000 patients. Rivaroxaban was developed in its first indication in just 78 months. Frank was also responsible for the successful development of Riociguat, a stimulator of soluble guanylate cyclase, approved to treat two forms of Pulmonary Hypertension.
Frank led the Therapeutic Area engaged in developing replacement therapies in hemophilia A including Damoctocog alfa pegol which was approved by EMA and FDA in 2018.
Frank's previous academic research experience was gained in UK, USA, Germany and Russia and he is the author of over 250 publications.
Dr Misselwitz commented: "I am excited to have the opportunity to be joining Actimed to help bring ACM-001 to the many patients for whom cancer related cachexia remains a significant unmet need, as well as developing Actimed's broader pipeline for muscle wasting disorders. As a Board member at Actimed, I am already very familiar with the Company and the impressive data amassed to date on ACM-001. I look forward to working with Actimed's outstanding team to bring this and other innovative new products to this vulnerable and under-served patient population."
About Actimed Therapeutics
Actimed Therapeutics is a clinical stage biopharmaceutical company focused on bringing innovation to the treatment of muscle wasting disorders to transform the care of an underserved and vulnerable patient population. Actimed was founded in 2017 by Stefan Anker and Andrew Coats, two world leading physicians in muscle wasting research.
The lead area of focus for Actimed is specifically in cachexia. Cachexia is a wasting disease that accompanies cancer and other serious chronic illnesses and is associated with significant morbidity and mortality. Despite its prevalence and devastating clinical effects, there is no approved drug for the treatment or prevention of cancer-related cachexia.
It has been estimated that cachexia affects 50–80% of cancer patients and accounts for up to 20% of cancer deaths. Treating cancer cachexia successfully may increase both the length and quality of life for cancer patients.
The lead product of Actimed, ACM-001 (S-pindolol), formerly known as MT-102, targets multiple pathways that drive cachexia and has generated promising proof of concept Phase II clinical data in cachexia patients. Actimed is currently preparing for further clinical studies in cachexia in Non-Small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC).
Actimed has a second, pre-clinical product for cancer cachexia, S-oxprenolol. With the acquisition of the global rights for S-oxprenolol in ALS, Actimed now has the opportunity to expand the development focus of the Company to include this additional indication where loss of body mass and muscle wasting can impact survival.